Weight loss response In clinical trials, people responded differently to weight loss drugs depending on their score from a genetic test
Neurobiology of Aging, 134, 45-58
It has been demonstrated to suppress the expression of SREBP-1c and FAS, key regulators of lipogenesis, while simultaneously promoting fatty acid oxidation through upregulation of peroxisome proliferator-activated receptors (PPARs)
The energy expenditure effects contribute to Retatrutide's superior weight loss efficacy compared to GLP-1-only therapies
Strict timing requirements: The complex dosing schedule can impact medication adherence
Les animaux taient rpartis en trois groupes : un groupe tmoin sans traitement, un groupe recevant une administration locale de L-carnitine et un groupe recevant une administration systmique, tous suivis pendant 14 jours